HUE054356T2 - Gátlási reakcióutak semlegesítése limfocitákban - Google Patents

Gátlási reakcióutak semlegesítése limfocitákban

Info

Publication number
HUE054356T2
HUE054356T2 HUE17702315A HUE17702315A HUE054356T2 HU E054356 T2 HUE054356 T2 HU E054356T2 HU E17702315 A HUE17702315 A HU E17702315A HU E17702315 A HUE17702315 A HU E17702315A HU E054356 T2 HUE054356 T2 HU E054356T2
Authority
HU
Hungary
Prior art keywords
lymphocytes
neutralization
inhibitory pathways
pathways
inhibitory
Prior art date
Application number
HUE17702315A
Other languages
English (en)
Inventor
Pascale Andre
Mathieu Blery
Caroline Denis
Carine Paturel
Nicolai Wagtmann
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57944387&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE054356(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of HUE054356T2 publication Critical patent/HUE054356T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
HUE17702315A 2016-01-21 2017-01-20 Gátlási reakcióutak semlegesítése limfocitákban HUE054356T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662281217P 2016-01-21 2016-01-21

Publications (1)

Publication Number Publication Date
HUE054356T2 true HUE054356T2 (hu) 2021-09-28

Family

ID=57944387

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17702315A HUE054356T2 (hu) 2016-01-21 2017-01-20 Gátlási reakcióutak semlegesítése limfocitákban

Country Status (21)

Country Link
US (3) US10870700B2 (hu)
EP (2) EP3405495B1 (hu)
JP (2) JP7301538B2 (hu)
KR (1) KR20180101549A (hu)
CN (2) CN108884163B (hu)
AU (1) AU2017208554B2 (hu)
CA (1) CA3012055A1 (hu)
CY (1) CY1124212T1 (hu)
DK (1) DK3405495T3 (hu)
ES (1) ES2871112T3 (hu)
HR (1) HRP20210778T1 (hu)
HU (1) HUE054356T2 (hu)
IL (1) IL260464B (hu)
LT (1) LT3405495T (hu)
PL (1) PL3405495T3 (hu)
PT (1) PT3405495T (hu)
RS (1) RS61901B1 (hu)
RU (1) RU2769569C2 (hu)
SG (2) SG10202000645SA (hu)
SI (1) SI3405495T1 (hu)
WO (1) WO2017125532A1 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
US10676523B2 (en) 2014-09-16 2020-06-09 Innate Pharma Treatment regimens using anti-NKG2A antibodies
JP6767362B2 (ja) 2014-09-16 2020-10-14 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． リンパ球における阻害経路の中和
CN107073116A (zh) 2014-10-23 2017-08-18 依奈特制药公司 使用抗nkg2a试剂治疗癌症
CN107850596B (zh) 2015-07-24 2020-12-04 先天制药公司 用于检测组织浸润nk细胞的方法
MA51995A (fr) 2018-03-13 2021-01-20 Innate Pharma Traitement du cancer de la tête et du cou
US20210024633A1 (en) 2018-03-28 2021-01-28 Ensemble Group Holdings Methods of treating cancer in subjects having dysregulated lymphatic systems
EA202092696A1 (ru) * 2018-05-15 2021-04-05 Медиммун Лимитед Лечение рака
AU2019380307A1 (en) * 2018-11-16 2021-07-01 Bristol-Myers Squibb Company Anti-NKG2A antibodies and uses thereof
EP4045535A1 (en) * 2019-10-14 2022-08-24 Innate Pharma Treatment of cancer with ilt-2 inhibitors
IL300588A (en) * 2020-08-12 2023-04-01 Biond Biologics Ltd Antibodies against ILT-2 and their use

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
DE60334453D1 (de) 2002-05-30 2010-11-18 Macrogenics Inc Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
EP1831258B2 (en) 2004-12-28 2023-06-07 Innate Pharma S.A. Monoclonal antibodies against nkg2a
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
JP5829004B2 (ja) 2006-06-30 2015-12-09 ノボ・ノルデイスク・エー／エス 抗ｎｋｇ２ａ抗体とその使用
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
US8747847B2 (en) 2008-02-11 2014-06-10 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
KR101573109B1 (ko) 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
EP3708190A1 (en) 2010-02-26 2020-09-16 Novo Nordisk A/S Stable antibody containing compositions
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
CN103635487B (zh) 2011-06-17 2016-10-12 诺沃—诺迪斯克有限公司 选择性消除侵蚀性细胞
MY193562A (en) 2011-08-01 2022-10-19 Genentech Inc Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
WO2016032334A1 (en) 2014-08-28 2016-03-03 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Cd94/nkg2a and/or cd94/nkg2b antibody, vaccine combinations
JP6767362B2 (ja) * 2014-09-16 2020-10-14 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． リンパ球における阻害経路の中和
US10676523B2 (en) 2014-09-16 2020-06-09 Innate Pharma Treatment regimens using anti-NKG2A antibodies
CN107073116A (zh) 2014-10-23 2017-08-18 依奈特制药公司 使用抗nkg2a试剂治疗癌症

Also Published As

Publication number Publication date
KR20180101549A (ko) 2018-09-12
RS61901B1 (sr) 2021-06-30
JP2019506391A (ja) 2019-03-07
RU2018125490A (ru) 2020-02-21
CN108884163A (zh) 2018-11-23
SG10202000645SA (en) 2020-03-30
EP3868787A1 (en) 2021-08-25
LT3405495T (lt) 2021-08-10
EP3405495A1 (en) 2018-11-28
RU2018125490A3 (hu) 2020-06-26
AU2017208554A1 (en) 2018-08-09
SG11201805831RA (en) 2018-08-30
AU2017208554B2 (en) 2024-02-15
HRP20210778T1 (hr) 2021-07-23
ES2871112T3 (es) 2021-10-28
PL3405495T3 (pl) 2021-10-11
US20210122821A1 (en) 2021-04-29
JP7301538B2 (ja) 2023-07-03
RU2769569C2 (ru) 2022-04-04
SI3405495T1 (sl) 2021-08-31
US20190031755A1 (en) 2019-01-31
DK3405495T3 (da) 2021-05-17
CN108884163B (zh) 2022-08-16
US20230303691A1 (en) 2023-09-28
CY1124212T1 (el) 2022-05-27
US10870700B2 (en) 2020-12-22
IL260464B (en) 2022-02-01
CN116327916A (zh) 2023-06-27
EP3405495B1 (en) 2021-02-24
JP2023134490A (ja) 2023-09-27
CA3012055A1 (en) 2017-07-27
WO2017125532A1 (en) 2017-07-27
PT3405495T (pt) 2021-05-14

Similar Documents

Publication Publication Date Title
ZA201702642B (en) Neutralization of inhibitory pathways in lymphocytes
IL260464B (en) Neutralization of inhibition pathways in lymphocytes
ZA201800542B (en) Threaded fastener
EP3316884A4 (en) THERAPEUTIC INHIBITING COMPOUNDS
IL288147A (en) ras inhibitory peptides and their uses
HK1252645A1 (zh) 按摩機
ZA201707923B (en) Medical bathing device
PL3285606T3 (pl) Ochrona ciała
ZA201800413B (en) Dry suit
EP3414686A4 (en) AUTOMATIC DETECTION OF MALFUNCTION IN SURGICAL TOOLS
IL260193A (en) Tlr inhibitory oligonucleotides and their use
SG11201701717UA (en) Antiviral agents and uses thereof
SG10201606767SA (en) Direct resistivity determination
SG11201710519PA (en) Evaluation of inhibitory circuit and use thereof
EP3387530C0 (en) SECURE COMPUTER
HK1209364A1 (en) Use of actinomyces naeslundii in the treatment or prevention of rheumatoid arthritis or related diseases
AU5563P (en) Viclow Acmena smithii
GB201607978D0 (en) Inhibitory compounds
HK1209356A1 (en) Use of sutterella wadsworthensis in the treatment or prevention of rheumatoid arthritis or related diseases
GB201608592D0 (en) QA processing UK
GB201521152D0 (en) Dictionary/thesaurus
GB201517185D0 (en) Towel
GB201508876D0 (en) Sanitary protection
GB201509863D0 (en) Shower arrangement
GB201508203D0 (en) Water Ect